

CURRICULUM VITAE

John James Crowley, Ph.D.

Current Address: Cancer Research And Biostatistics
1505 Westlake Ave N, STE 750
Seattle, WA 98109-3050
www.crab.org

Phone: (206) 839-1720

Email: johnc@crab.org

Education: Pomona College, BA, (Mathematics), 1968
University of Washington, MS,
(Biomathematics), 1970
University of Washington, Ph.D.,
(Biomathematics), 1973

Positions:

NIH Post-doctoral Fellow, Department of Statistics and Division of Biostatistics, Department of Community and Preventive Medicine, Stanford University, 1973-74.
Assistant Professor, Departments of Human Oncology and Statistics, University of Wisconsin-Madison, 1974-79.
Associate Professor, Departments of Human Oncology and Statistics, University of Wisconsin-Madison, 1979-81.
Associate Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1981-84.
Associate Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1981-84.
Program Head, Biostatistics, Fred Hutchinson Cancer Research Center, 1983-1994.
Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1984-2001.
Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1984-2005.
Group Statistician and Director of Statistical Center, Southwest Oncology Group, 1984-2012.
President and Chief Executive Officer, Cancer Research And Biostatistics, 1997-2014.
Joint Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 2001-2012.
Board Chair, Cancer Research And Biostatistics, 2014-present.
Chief of Strategic Alliances, Cancer Research And Biostatistics, 2015-present.
Affiliate Professor, School of Public Health, Oregon Health and Science University, 2016 – present.
Visiting Professor, Graduate School of Cancer Science and Policy, National Cancer Center, Republic of Korea, 2016-2018.

Honors:

Spiegelman Award, American Public Health Association, 1985
Fellow, American Statistical Association, 1988
Fellow, American Association for the Advancement of Science, 1991
First Annual Kashinath Patil Lecturer, 1999
Marvin Zelen Leadership Award in Statistical Science, 2013
Norman Breslow Lecturer, 2013
Fellow, Society for Clinical Trials, 2016

PUBLICATIONS:

1. Breslow N, Crowley J. Large sample properties of the life table and PL estimates under random censorship. *Annals of Statistics* 2:437-453, 1974.
2. Crowley J. Asymptotic normality of a new nonparametric statistic for use in organ transplantation studies. *JASA* 69:1006-1011, 1974.
3. Crowley J. A note on some recent likelihoods leading to the log rank test. *Biometrika* 61:533-538, 1974.
4. Crowley J, Breslow N. Remarks on the conservatism of $(0-E)^2/E$ in survival data. *Biometrics* 31:957-962, 1975.
5. Alderman EL, Davies RO, Crowley J, et al. Dose response effectiveness of propranolol for the treatment of angina pectora. *Circulation* 51:964-975, 1975.
6. Crowley J, Hu M. Covariance analysis of heart transplant survival data. *JASA* 72:27-36, 1977.
7. Rose DP, Stauber P, Thiel A, Crowley J, et al. Plasma dehydro-epiandrosterone sulfate, androstenedione and cortisol, and urinary free cortisol excretion in breast cancer. *Eur J Cancer* 3:43-47, 1977.
8. Gould MN, Jirtle R, Crowley J, Clifton K. Re-evaluation of the number of cells involved in the neutron induction of mammary neuroplasms. *Cancer Res* 38:189-192, 1978.
9. Gould MN, Clifton KH, Crowley J. Effects of endocrinological conditions associated with acute versus chronic lactation on the incidence of mammary carcinomas in irradiated rats: Brief communication. *J Natl Cancer Inst* 60:469-471, 1978.
10. Clifton KH, Crowley J. Effects of radiation type & dose & role of glucocorticoids in mammary tumor induction in MtT-grafted rats. *Cancer Res* 38:1507-1513, 1978.
11. Baumgartener LE, Crowley J, Entine S, et al. Influence of sire on BLV infection in progeny. *Zbl. Vet Med B* 25:202-210, 1978.
12. Hoogerland DL, Buchler DA, Crowley J, et al. Estrogen use-- risk of endometrical carcinoma. *Gyn Oncol* 6:451-458, 1978.
13. Dubner HN, Crowley J, Schilling RF. Prognostic value of nucleoli and cell size in chronic lymphocytic leukemia. *Am J Hematol* 4:337-341, 1978.
14. Schilling RF, Crowley J. Prognostic factors in chronic myelocytic leukemia. *Am J Hematol* 7:1-10, 1979.
15. Crowley J. Some extensions of the log rank test. In Lecture Notes in Medical Informatics 4. Clinical Trials in "Early" Breast Cancer--Methodologic & Clinical Aspects of Treatment Comparisons. Proceedings, Heidelberg Germany 1978. HR Scheurlen, G Weckesser, I Armbruster, eds. New York: Springer-Verlag, pp. 213-223, 1979.
16. Hunter WG, Crowley J. Hazardous substances, the environment & public health: A statistical viewpoint. *Environ Hlth Perspec* 32:241-254, 1979. Translated into German into two papers: *Arbeitsmedizin, Sozialmedizin, Preventivmedizin* 17:142-146 and 177-181, 1982.
17. Coates AS, Klopp RG, Zarling JM, Borden EC, Crowley J, Carbone PP. Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of energy. *Cancer Immunol Immunother* 7:175-179, 1979.
18. Pandya KJ, Tormey DC, Davis TE, Falkson G, Banerjee TK, Crowley J. A phase II trial of 6-thioguanine in metastatic breast cancer. *Cancer Treat Rep* 64:191-192, 1980.
19. Pandya KJ, Whitehead R, Crowley J, et al. Elevated plasma aldosterone levels in patients with liver metastases. A rationale for spirono-lactone therapy. *JAMA* 244:171-172, 1980.
20. Hogan TE, Borden EC, Freeburg BL, Vieau J, Hsieh F-Y, Crowley J. Enhancement in recall antigen responses by frequent, repetitive skin testing with candida, mumps, and streptokinase-streptodornase in 38 normal adults. *Cancer Immunol Immunother* 10:27-31, 1980.
21. Hogan TE, Borden EC, Loenhardt PH, Voelkel JG, Crowley J. Growth modification in human cells by Poly I: Poly C Amphotericin B Methyl Ester. In Interferon: Properties & Clinical Uses. A Kahn, NO Hill, GL Dorn; eds. Dallas: Leland Fikes Foundation Press, pp. 609-618, 1980.

22. Davis TE, Kahn L, Tormey DC, Larson FC, Anderson SA, Crowley J, Carey RN. Clinical studies of a fast homoarginine-sensitive alkaline phosphate (FHAP) in patients with cancer. *Cancer Res* 41:1110-1113, 1981.
23. Tunca JC, Buchler DA, Mack EA, Ruzicka FF, Crowley J, Carr WF. The management of ovarian cancer caused bowel obstruction. *Gynecol Oncol* 12:186-192, 1981.
24. Chang Y-C, Falkson G, Tormey DC, Crowley J. Phase I-II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine & prednisone in advanced breast cancer. *Cancer Clin Trials* 4:77-79, 1981.
25. Robins HI, Tormey DC, Skelley MJ, Falkson G, Crowley J, Ramirez G, Falkson H. Vindesine: A phase II trial in advanced breast cancer patients. *Cancer Clin Trials* 4(4):371-375, 1981.
26. Breslow N, Crowley J. Contribution to the discussion of the paper "Survival times: Aspects of partial likelihood" by David Oakes. *Intl Stat Review* 49:255-257, 1981.
27. Jirtle RL, Michalopoulos G, McLain JR, Crowley J. Transplantation system for determining the clonogenic survival of parenchymal hepatocytes exposed to ionizing radiation. *Cancer Res* 41:3512-3518, 1981.
28. Tormey DC, Davis TE, Falkson G, Crowley J. Combination chemotherapy + tamoxifen in advanced breast cancer. *Reviews on Endocrine-Related Cancer Supplement* 9, pp. 484-489, 1981.
29. Wiley AL, Wirtanen GW, Davis TE, Ramirez G, Davis HL, Carbone PP, Wolberg WH, Johnson RO, Crowley J. Preliminary results on the treatment of unresectable pancreatic carcinoma with a combination of precision (intra arterial) chemotherapy & precision radiation therapy. In *Pancreatic Cancer: New Directions in Therapy Management*. I Cohn, ed. New York: Masson Pub Co, pp. 97-106, 1981.
30. Brookmeyer R, Crowley J. A confidence interval for the median survival time. *Biometrics* 38:29-41, 1982.
31. Tormey DC, Falkson G, Crowley J, et al. Dibromodulcitol & adriamycin + tamoxifen in advanced breast cancer. *Am Journal of Clinical Oncology Cancer: Clinical Trials* 5:33-39, 1982.
32. Schilling RF, McKnight B, Crowley J. Prognostic value of serum lactic dehydrogenase level in Hodgkin's disease. *J Laboratory Clin Med* 99:382-387, 1982.
33. Brookmeyer R, Crowley J. A k-sample median test for censored survival data. *JASA* 77:433-440, 1982.
34. Crowley J, Voelkel J. Contribution to the discussion of "linear nonparametric tests for comparison of counting processes," by Anderson, Borgan, Gill and Kelding. *Intl Stat Review* 50:247-248, 1982.
35. Chang YC, Falkson G, Tormey DC, Crowley J. A pilot study of mitomycin C & tamoxifen (MT) versus dibromodulcitol adriamycin, & tamoxifen (DAT). *Am Journal of Clinical Oncology* 5:521-525, 1982.
36. Borden EC, Davis TE, Crowley J, et al. Interim analysis of a trial of Levamisole & 5-Fluorouracil in metastatic colorectal carcinoma. In *Immunotherapy of Human Cancer*. W Terry, SA Rosenberg; eds. New York: Elsevier North Holland Inc, pp. 231-235, 1982.
37. Crowley J, Liu PY, Voelkel JG. Estimation of the ratio of hazard functions. *Survival Analysis: IMS Lecture Notes, Monograph Series, Volume 2*. J Crowley, RA Johnson; eds. Hayward CA: The Institute of Mathematical Statistics, pp. 56-73, 1982.
38. Leurgans S, Tsai W-Y, Crowley J. Freund's bivariate exponential distribution & censoring. In *Survival Analysis IMS Lecture Notes Monograph Series, Vol 2*. J Crowley, RA Johnson; eds. Hayward CA: The Institute of Mathematical Statistics, pp. 230-242, 1982.
39. Meeker TC, Siegel MS, Shiota FM, Crowley J, McGuffin RW. Toxicity of amphotericin B, miconazole & ketoconazole to human granulocyte progenitor cells *in vitro*. *Antimicrob Agents Chemother* 23(1):169-171, 1983.
40. Kennedy MS, Deeg HJ, Siegel M, Crowley J, Storb R, Thomas ED. Acute renal toxicity by combined use of amphotericin B & cyclosporin A after allogenic marrow transplantation. *Transplantation* 35(3):211-215, 1983.
41. Hsieh F-Y, Crowley J, Tormey DC. Some test statistics for use in multistate survival analysis. *Biometrika* 70:111-119, 1983.

42. Wade JC, DeJongh CA, Newman KA, Crowley J, et al. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. *J Infect Dis* 147:624-634, 1983.
43. Crowley J, Storer BE. Comment on "A reanalysis of the Stanford heart transplant data" by M Aitkin, N Laird, B Francis. *JASA* 78:277-281, 1983.
44. Crowley J: Book review of "Survival Analysis" by Rupert Miller. *American Scientist*, 1983.
45. Voelkel JG, Crowley J. Nonparametric inference for a class of semi-Markov processes with censored observations. *Annals of Statistics* 12:142-160, 1984.
46. Schilling RF, McKnight B, Crowley J. Prognostic value of blood glucose in Hodgkin's disease. *Journal of Clinical Oncology* 2:828-830, 1984.
47. Wade JU, Day LM, Crowley J, et al. Recurrent herpes simplex virus infection after marrow transplant: Role of the specific immune response & acyclovir treatment. *J Infec Dis* 149:750-756, 1984.
48. McKnight B, Crowley J. Tests for differences in tumor incidence based on animal carcinogenesis experiments. *JASA* 79:639-648, 1984.
49. Appelbaum FR, Dahlberg S, Thomas ES, Buckner CD, Cheever MA, Clift RA, Crowley J, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. *Ann Intern Med* 101:581-588, 1984.
50. Crowley J, Breslow N. Statistical analyses of survival data. In *Annual Review of Public Health*, Vol 5. N Breslow, ed. Palo Alto CA: Annual Reviews Inc, pp. 385-441, 1984.
51. Storer BE, Crowley J. Diagnostics for Cox regression. *Proceedings of the 12th International Biometrics Conference*, pp. 163-175, 1984.
52. Storer BE, Crowley J. A diagnostic for Cox regression and general conditional likelihoods. *JASA* 80:139-147, 1985.
53. Crowley J. Contribution to Panel Discussion, NCI Symposium on Methodology and Quality Assurance in Cancer Clinical Trials, Session 1: Biometric Issues. *Cancer Treat Rep*, 69:1079-1080, 1985.
54. Green SJ, Crowley J. On robust estimation with arbitrarily right-censored data. *Statistics and Probability Letters* 4:303-308, 1986.
55. Weiss GR, Crowley J, Von Hoff DD, et al. Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. *Cancer Treat Rep* 70:1123-1124, 1986.
56. Livingston RB, Schulman S, Mira JG, Harker G, Vogel S, Coltman CA, Jr., Rivkin SE, Budd GT, Grever MR, Crowley J. Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: A Southwest Oncology Group study. *Cancer Treat Rep* 70:1395-1401, 1986.
57. Tsai WY, Leurgans S, Crowley J. Nonparametric estimation of a bivariate survival function in the presence of censoring. *Annals of Statistics* 14(4):1351-1365, 1986.
58. Goodwin JW, Crowley J, Tranum B, et al. Phase II trial of spiro-germanium in central nervous system tumors: A Southwest Oncology Group study. *Cancer Treat Rep* 71(1):99-100, 1987.
59. Goodman GE, Yen YP, Cox TC, Crowley J. The effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. *Cancer Research* 47:2295-2304, 1987.
60. Kies MS, Mira JG, Crowley J. Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group study. *Journal of Clinical Oncology* 5(4):592-600, 1987.
61. Shields AF, Coonrod DV, Quackenbush RC, Crowley J. Cellular sources of thymidine nucleotides: Studies for PET. *J Nuclear Med* 28:1435-1440, 1987.
62. Lenhard Jr. RE, Enterline JP, Crowley J, Ho GYF. The effects of distance from primary treatment centers on survival among patients with multiple myeloma. *Journal of Clinical Oncology* 5(10):1640-1645, 1987.
63. Stuckey WJ, Crowley JJ, Baker LH, et al. Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: A Southwest Oncology Group study. *Cancer Treat Rep* 71(11):1095-1096, 1987.

64. Radosevich CA, Kies MS, Bannon DJ, Mira JG, Crowley J, Livingston RB. Long-term follow-up after induction chemotherapy with or without chest radiation in limited small cell lung cancer (for the Southwest Oncology Group). Proceedings of the 1987 Adjuvant Therapy Conference.
65. Early Breast Cancer Trialists' Collaborative Group (Member, Working Party). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. *New Engl J Med* 319(26):1681-1692, 1988.
66. Rainey JM, Hill JB, Crowley J. Evaluation of fludarabine phosphate in small cell carcinoma: A Southwest Oncology Group study. *Invest New Drugs* 6:45-46, 1988.
67. Sause WT, Crowley J, Eyre HJ, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases. *J Neuro Oncol* 6:107-112, 1988.
68. Jones MP, Crowley J. A general class of nonparametric tests for survival analysis. *Biometrics* 45:157-170, 1989.
69. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Jr, Crowley J. Quality of life endpoints in cancer clinical trials: Review and recommendations. *J Natl Cancer Inst* 81(7):485-495, 1989.
70. Cancer and Leukemia Group B, Children's Cancer Study Group, Eastern Cooperative Oncology Group, Southwest Oncology Group (John J. Crowley). A compendium of statistical terms and procedures used in cancer clinical trials. In *Advances in Oncology*. J Anderson, K Propert, eds. Vol. 5, No. 2, pp.7-30, 1989.
71. Livingston RB, McCracken JD, Crowley J. Southwest Oncology Group trial of simultaneous chemotherapy and radiation therapy in limited small cell lung cancer. In *Small cell lung cancer and non-small cell lung cancer*. RJ Gralla and LH Einhorn. eds., Royal Society of Medicine Services International Congress and Symposium Series No. 150, Royal Society of Medicine Services Limited, pp. 43-49, 1989.
72. Goodman GE, Crowley J, Blasko JC, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: A Southwest Oncology Group study. *Journal of Clinical Oncology* 8(1):39-47, 1990.
73. Tsai WY, Crowley J. A large sample study of generalized maximum likelihood estimators from incomplete data via self-consistency. *Annals of Statistics* 13:1317-1334, 1985. Correction: *Annals of Statistics* 18:470, 1990.
74. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA. Prognostic value of pretreatment serum β_2 microglobulin in myeloma: A Southwest Oncology Group study. *Blood* 75(4):823-830, 1990.
75. Karanes C, Crowley J, Sawkar L, et al. Aclacino-mycin A in the treatment of multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 8:101-104, 1990.
76. Edelstein MB, Crowley J, Valeriote FA, et al. A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 8:583-589, 1990.
77. McCracken JD, Janaki LM, Crowley J, et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 8(5):892-898, 1990.
78. O'Bryan RM, Crowley J, Kim PN, et al. Comparison of etoposide and cisplatin with bis-chloroethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group study. *Cancer* 65(4):856-860, 1990.
79. Liu PY, Voelkel J, Crowley J. On the ratio of hazard functions in the presence of a nuisance covariate. *Statistics & Probability Letters* 10:135-140, 1990.
80. Jones MP, Crowley J. Asymptotic properties of a general class of nonparametric tests for survival analysis. *Annals of Statistics* 18:1203-1220, 1990.
81. Salmon SE, Tesh D, Crowley J, et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 8(9):1575-1584, 1990.

82. Albain KS, Crowley J, LeBlanc M, Livingston RB. Determinants of improved outcome in small cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. *Journal of Clinical Oncology* 8(9):1563-1574, 1990.
83. Grever MR, Crowley J, Salmon S, et al. Phase II investigation of pentostatin in multiple myeloma: A Southwest Oncology Group study. *J Natl Cancer Inst* 82(22):1778-1780, 1990.
84. Taylor CW, Crowley J, Williamson SK, et al. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study. *Journal of Clinical Oncology* 8(11):1811-1817, 1990.
85. Sause WT, Crowley J, Morantz R, et al. Solitary brain metastases: Results of an RTOG/SWOG protocol evaluating surgery +RT versus RT alone. *Am Journal of Clinical Oncology* 13(5):427-432, 1990.
86. Kraut EH, Crowley J, Grever MR, et al. A phase II study of fludarabine phosphate in multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 8:199-200, 1990.
87. Gentleman R, Crowley J. Smoothing censored data. Proceedings of the XVth International Biometric Conference pp.111-121, 1990.
88. Early Breast Cancer Trialists' Collaborative Group (Member, Working Party). Treatment of Early Breast Cancer Volume I, Worldwide Evidence 1985-1990. Oxford University Press, 1990.
89. Vance RB, Crowley J, Macdonald JS, Ahmann FR. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma: A Southwest Oncology Group study. *Invest New Drugs* 9:73-75, 1991.
90. Goodman GE, Crowley J, Livingston RB, et al. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high dose cyclophosphamide: A Southwest Oncology Group study. *Journal of Clinical Oncology* 9:453-457, 1991.
91. Anderson JR, Crowley J, Propert KJ. Interpretation of survival data in clinical trials. *Oncology* 5(2):104-110, 1991.
92. Taylor SA, Crowley J, Vogel FS, et al. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial. *Invest New Drugs* 9:195-197, 1991.
93. Higano CS, Crowley J, Livingston RB, et al. A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. *Cancer* 67(10):2439-2442, 1991.
94. Albain KS, Crowley J, Livingston RB. Long-term survival and toxicity in small cell lung cancer, expanded Southwest Oncology Group experience. *Chest* 99:1425-1432, 1991.
95. Ellis GK, Crowley J, Livingston RB, et al. Cisplatin and novobiocin in the treatment of non-small cell lung cancer. *Cancer* 67(12):2969-2973, 1991.
96. Grunberg SM, Crowley J, Livingston RB, et al. Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study. *Cancer Chemother Pharmacol* 28:211-213, 1991.
97. Gentleman R, Crowley J. Graphical methods for censored data. *JASA* 86(515):678-682, 1991.
98. Albain KS, Crowley J, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. *Journal of Clinical Oncology* 9(9):1618-1626, 1991.
99. Weick JK, Crowley J, Natale RB, et al. A randomized trial of five cisplatin-containing treatments in patient with metastatic non-small-cell lung cancer: A Southwest Oncology Group study. *Journal of Clinical Oncology* 9(7):1157-1162, 1991.
100. Taylor SA, Crowley J, Pollock TW, et al. Objective anti-tumor activity of Acivin (AT-125) in patients with recurrent CNS malignancies; A Southwest Oncology Group trial. *Journal of Clinical Oncology* 9(8):1476-1479, 1991.
101. Gentleman R, Crowley J. Local full likelihood estimation for the proportional hazards model. *Biometrics* 47:1283-1296, 1991.
102. Durie BGM, Crowley J, Coltman CA, et al. Phase II evaluation of bisantrene in refractory multiple myeloma, A Southwest Oncology Group study. *Invest New Drugs* 9:329-331, 1991.

103. Saeed SM, Stock-Novack D, Pohlod R, Crowley J, Salmon SE. Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: A Southwest Oncology Group study. *Blood* 78(12):3281-3287, 1991.
104. Hanson KH, Crowley J, Salmon SE, et al. Evaluation of amonafide in refractory and relapsing multiple myeloma: A Southwest Oncology Group study. *Anti-Cancer Drugs* 2:247-250, 1991.
105. Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J. Alpha-Interferon for remission maintenance: Preliminary report on the Southwest Oncology Group study. *Seminars in Oncology* 18(5):33-36 Suppl 7, 1991.
106. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy; 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. *The Lancet* 339(8784):1-15; 71-85, 1992.
107. Mortimer JE, Crowley J, Eyre H, et al. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. *Cancer* 69(5):120-123, 1992.
108. LeBlanc M, Crowley J. Relative risk trees for censored survival data. *Biometrics* 48:411-425, 1992.
109. Goodman PJ, Crowley J, Benson C. Creation of a semiannual report for a multicentre cooperative clinical trials group. *Stat Med* 11:1367-1376, 1992.
110. Williamson S, Crowley J, Livingston R, et al. Phase II trial of piroxantrone in advance non-small cell carcinoma of the lung. *Invest New Drugs* 10:29-30, 1992.
111. Jones MP, Crowley J. Nonparametric tests of the Markov model for survival data. *Biometrika* 79(3):513-522, 1992.
112. Gentleman R, Crowley J. A graphical approach to the analysis of censored data. *Breast Cancer Res Treat* 22:229-240, 1992.
113. Chou DK, Guy AW, Kunz LL, Johnson RB, Crowley JJ, Krupp JH. Long-term, low-level microwave irradiation of rats. *Bioelectromagnetics* 13:469-496, 1992.
114. Crowley J, Green S. Comment on "Evaluating Therapeutic Interventions" by Thomas R. Fleming. *Statistical Science* 4:441-443, 1992.
115. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. *Blood* 80(7):1666-1672, 1992.
116. Liu PY, Green S, Wolf M, Crowley J. Testing against ordered alternatives for censored survival data. *JASA* 88(421):153-160, 1993.
117. Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. *J Neurooncol* 15:75-77, 1993.
118. Rusch VW, Albain KS, Crowley JJ, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. *J Thorac Cardiovasc Surg* 105(1):97-106, 1993.
119. Green S, Crowley J. Data monitoring committees for Southwest Oncology Group clinical trials. *Stat Med* 12:451-455, 1993.
120. Taylor SA, Crowley J, Townsend J, et al. Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies. A Southwest Oncology Group study. *J Neurooncol* 15:181-184, 1993.
121. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. *Journal of Clinical Oncology* 11(5):873-878, 1993.
122. LeBlanc M, Crowley J. Survival trees by goodness of split. *JASA* 88:457-467, 1993.
123. Williamson SK, Crowley J, Livingston RB, Weiss G: Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. *Invest New Drugs* 11:81-83, 1993.
124. Chapman R, Crowley J, Lucas JG, et al. Mitogauzone, cisplatin, and vinblastine in advance non-small cell lung cancer. A Southwest Oncology Group study. *Invest New Drugs* 11:91-92, 1993.

125. Livingston RB, Crowley J, Thompson T, et al. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest Oncology Group study. *Cancer* 71(11):3509-3513, 1993.
126. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *Journal of Clinical Oncology* 11(7):1276-1285, 1993.
127. Eyre HJ, Crowley J, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A Southwest Oncology Group study. *J Neurosurg* 78:909-914, 1993.
128. Liu PY, Dahlberg S, Crowley J. Selection designs for pilot studies based on survival. *Biometrics* 49:391-398, 1993.
129. Grunberg SM, Crowley J, Livingston R, et al. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. *Journal of Clinical Oncology* 11(8):1598-1601, 1993.
130. Benedetti J, Green S, Lee ML, Crowley J. Report of the ad hoc committee on design of an experiment on double-blind refereeing. *Statistical Science* 8(3):318-330, 1993.
131. Liu PY, Voelkel JO, Crowley J, Wolf M. Sufficient conditions for treatment responders to have longer survival than non-responders. *Stat & Prob Letters* 18:205-208, 1993.
132. Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study #8605 and an analysis of the recurrent disease data base. *Cancer* 72(4):1184-1191, 1993.
133. Coiffier B, Philip T, Burnett AK, Symann ML and Panel. Consensus conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies, Lyon, June 4-6, 1993. *Ann Oncol* 5:19-23, 1994.
134. Barlogie B, Anderson K, Berensen J, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles R, Reece D, Reiffers J, Salmon S, Tricot G, Vesole D. Transplants for multiple myeloma. *J Cell Biochem, Suppl* 18B:56, 1994.
135. Barlogie B, Crowley J, Salmon SE, et al. Phase II study of carboplatin (CBDCA) in refractory multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 12:53-55, 1994.
136. Crowley J, Green S, Liu PY, Wolf M. Data monitoring committees and early stopping guidelines: The Southwest Oncology Group experience. *Stat Med* 13:1391-1399, 1994.
137. Harrington D, Crowley J, George SL, et al. The case against independent monitoring committees. *Stat Med* 13:1411-1414, 1994.
138. Rusch VW, Albain KS, Crowley J, et al. Neoadjuvant therapy : A novel and effective treatment for stage IIIb non-small cell lung cancer. *Ann Thorac Surg* 58:290-295, 1994.
139. Hazuka MB, Crowley J, Bunn PA, et al. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: Results of a phase II Southwest Oncology Group study. *Journal of Clinical Oncology* 12(9):1814-1820, 1994.
140. Jagannath S, Vesole DH, Tricot G, Crowley J, Salmon SE, Barlogie B. Hemopoietic stem cell transplants for multiple myeloma. *Oncology* 8(11):89-103, 1994.
141. Salmon SE, Crowley JJ, Grogan TM, et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 12(11):2405-2414, 1994.
142. Vesole D, Barlogie B, Jagannath S, Cheson B, Tricot G, Crowley J. High dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. *Blood* 84(3):950-956, 1994.
143. Crowley J. Perioperative portal vein chemotherapy. In ASCO Educational Book from 30th Annual Meeting, Dallas TX, May 14-17, pp. 171-175, 1994.
144. Crowley J, Liu PY: Book review of "Statistical Models Based on Counting Processes" by PK Anderson, O Borgan, RD Gill, and N Keiding. *JASA*, p. 356, 1994.
145. LeBlanc M, Crowley J. Semiparametric regression functionals. *JASA* 90(429):95-105, 1995.
146. Dalton WS, Crowley J, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study. *Cancer* 75(3):815-820, 1995.

147. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA, Brawley OW, Ford LG. Design of the Prostate Cancer Prevention Trial (PCPT). *Control Clin Trials* 16:150-163, 1995.
148. Piantadosi S, Crowley J. An implicitly defined parametric model for censored survival data and covariates. *Biometrics* 51:249-258, 1995.
149. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B. Peripheral blood stem cell transplantation for multiple myeloma-identification of favorable variables for rapid engraftment in 225 patients. *Blood* 85(2):588-596, 1995.
150. LeBlanc M, Crowley J. Step-function covariate effects in the proportional-hazards model. *The Canadian Journal of Statistics* 23(2):109-129, 1995.
151. Williamson SK, Crowley JJ, Livingston RB, et al. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. *Invest New Drugs* 13:67-71, 1995.
152. Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. *Journal of Clinical Oncology* 13(7):1632-1641, 1995.
153. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. *British Medical Journal* 311:899-909, 1995.
154. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. *N Engl J Med* 333(22):1444-1455, 1995.
155. Kelly K, Crowley J, Bunn PA, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. *Journal of Clinical Oncology* 13(12): 2924-2930, 1995.
156. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group Phase II study 8805. *Journal of Clinical Oncology* 13(8):1880-1892, 1995.
157. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy. *Bone Marrow Transplant* 16:7-11, 1995.
158. Barlogie B, Anderson K, Berenson J, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles R, Reece D, Reiffers J, Salmon S, Tricot G, and Vesole D. Transplants for Multiple Myeloma. In: K. Dickie and A. Keating (eds.): Autologous Marrow and Blood Transplantation. Proceedings of the Seventh International Symposium, Arlington, Texas, pp. 399-410, 1995.
159. Crowley J, Leblanc M, Gentleman R, Salmon S. Exploratory methods in survival analysis. In: IMS Lect Notes 27:55-77, 1995.
160. LeBlanc M, Crowley JJ. A review of tree-based prognostic models. In: Recent Advances in Clinical Trial Design and Analysis. Peter F. Thall (ed), Kluwer Academic Publishers, pp. 113-124, 1995.
161. Modiano M, Villar-Werstler P, Crowley J, Salmon S. Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229. *Journal of Clinical Oncology* 14(3):974-977, 1996.
162. Figlin RA, Crowley JJ, Jacobs EL, et al. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma: A phase II study of the Southwest Oncology Group. *Cancer* 78:998-1003, 1996.
163. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B. Autotransplants in multiple myeloma: What have we learned? *Blood* 88(3):838-847, 1996.
164. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. *The Lancet* 348(9036):1189-1196, 1996.

165. Vesole DH, Jagannath S, Tricot G, Crowley J, Barlogie B. Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. *Cancer Invest* 14(4):378-391, 1996.
166. Crowley J: Book review of "Analysing Survival Data from Clinical Trials and Observational Studies" by Ettore Marubini and Maria Grazia Valsecchi. *Control Clin Trials* 17:353-55, 1996.
167. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. *Journal of the Cancer Institute* 89(7):497-505, 1997.
168. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G, Barlogie B. Feasibility and cost effectiveness of outpatient autotransplants in multiple myeloma. *Bone Marrow Transplant* 20:445-450, 1997.
169. Grozea PN, Crowley JJ, Canfield VA, et al. Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma. A phase II study of the Southwest Oncology Group. *Cancer* 80(6):1029-1033, 1997.
170. Higano CS, Crowley JJ, Veith RV, Livingston RB. A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer. A Southwest Oncology Group study. *Invest New Drugs* 15:153-156, 1997.
171. Thompson IM, Coltman CA, Crowley J. Chemoprevention of prostate cancer: The Prostate Cancer Prevention Trial. *The Prostate* 33:217-221, 1997.
172. Barlogie B, Jagannath S, Vesole D, Naucke S, Cheson B, Matrox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. *Blood* 89(9):789-793, 1997.
173. Gandara DR, Edelman MJ, Crowley JJ, et al. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: A Southwest Oncology Group study. *Cancer Chemother Pharmacol* 41:75-78, 1997.
174. Crowley J, LeBlanc M, Jacobson J, Salmon S. Some exploratory tools for survival analysis. In: *Lecture Notes In Statistics. Proceedings of the first Seattle symposium in biostatistics: survival analysis*, Seattle, Washington, pp. 199-229, 1997.
175. Weick J, Crowley J, Natale R, et al. A randomized trial of five cisplatin-containing treatment in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group Study. *Classic Papers and Current Comments* 2(1):172-177, 1997.
176. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. *Classic Papers and Current Comments* 2(1):145-158, 1997.
177. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neeffe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. *Classic Papers and Current Comments* 2(1):178-184, 1997.
178. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer. The Southwest Oncology Group experience. *Classic Papers and Current Comments* 2(1):135-144, 1997.
179. Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 16(3):890-896, 1998.
180. Thomas CR, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229). *Int J Radiat Oncol Biol Phys* 40(5):1039-1047, 1998.
181. Antman K, Crowley JJ, Balcerzak SP, et al. A Southwest Oncology Group and cancer and leukemia group b phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma and rhabdomyosarcoma. *American Cancer Society* 82(7):1288-1295, 1998.

182. Kraut EH, Crowley JJ, Wade JL, et al. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. *Journal of Clinical Oncology* 16(2):589-592, 1998.
183. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *The Lancet* 351(9114):1451-1467, 1998.
184. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. *Journal of Clinical Oncology* 16(7):2459-2465, 1998.
185. Lau DH, Crowley JJ, Gandara DR, et al. Southwest Oncology Group Phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III Non-small-cell lung cancer. *Journal of Clinical Oncology* 16(9):3078-3081, 1998.
186. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. *The Lancet* 352(9132):930-942, 1998.
187. Tsai WY and Crowley J. A note on nonparametric estimators of the bivariate survival function under univariate censoring. *Biometrika* 85(3):573-580, 1998.
188. Berenson J, Crowley J, Barlogie B, Salmon S: Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma (MM) patients. *Blood* 92:1305, 1998.
189. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Alexanian R, Crowley J, and Tricot G. Long term follow-up after high dose therapy for high risk multiple myeloma. *Bone Marrow Transplant* 21(11):1101-1107, 1998.
190. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan R, Munshi N, Fassas A, Mattox S, Bracy D, Crowley J, Vesole D, Barlogie B. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? *Bone Marrow Transplant* 21(9):887-892, 1998.
191. Miller TP, Crowley JJ, Mira J, Schwartz JG, Hutchins L, Baker L, Natale R, Chase EM, Livingston RB. A randomized trial of chemotherapy and radiotherapy for stage III Non-small cell lung cancer. *Cancer Therapeutics* 1(4):229-36, 1998.
192. Crowley, J. American Society of Clinical Oncology Educational Book. Los Angeles: ASCO Thirty-Fourth Annual Meeting; 1998. Interpreting clinical trials 2: Factorial designs, subset analyses, and intent to treat.
193. Zhang H, Crowley J, Sox HC, Jr, Olshen RA. Tree-structured statistical methods. In: Armitage P; Colton T, editors. *Encyclopedia of Biostatistics*. Volume 6. Chichester: John Wiley & Sons; 1998. p. 4561-4573.
194. Green SJ, Crowley J, Blumenstein B, Benedetti J. An open letter to the ASCO leadership and membership. Letter to the editor. *Journal of Clinical Oncology* 16:3478, 1998.
195. Barlogie B, Jagannath S, Desikan R, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar M, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. *Blood* 93(1):55-65, 1999.
196. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med* 18:695-706, 1999.
197. Hesketh P, Crowley JJ, Burris III H, et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group Phase II Trial. *The Cancer Journal From Scientific American* 5(4):237-241, 1999.
198. Vesole D, Crowley JJ, Catchatourian R, et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group Phase II Trial. *Journal of Clinical Oncology* 17(7):2173-2179, 1999.
199. Leigh BR, Gandara DR, Crowley JJ, Furuse K, Livingston RB, Fukushima M, Coltman Jr. C. Summary of the proceedings of the United States-Japan lung cancer clinical trials summit: San Francisco, CA, 20-22 November, 1998. *Lung Cancer* 24:181-191, 1999.

200. LeBlanc M, Crowley J. Using the bootstrap for estimation in group sequential design: An application to a clinical trial for nasopharyngeal cancer. *Stat Med* 18:2635-2644, 1999.
201. Livingston R and Crowley J. Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer. *Journal of Clinical Oncology* 17(11):22-24, 1999.
202. Sigal S, Mehta J, Desikan R, et al. Antitumor Activity of thalidomide in refractory multiple myeloma. *N Engl J Med* 341(21):1565-1571, 1999.
203. LeBlanc M and Crowley J. Adaptive regression splines in the Cox model. *Biometrics* 55:204-213, 1999.
204. Grunberg SM, Crowley J, Hande KR, Giroux D, Munshi N, Lau DHM, Schroder LE, Zangmeister MH, Balcerzak SP, Hynes HE, Gandara DR. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide: A Southwest Oncology clinical and pharmacokinetic study. *Cancer Chemother Pharmacol* 44:461-468, 1999.
205. Hutchins L, Unger J, Crowley JJ, Coltman C, Albain K. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. *N Engl J Med* 341(27):2061-2067, 1999.
206. Pisters KMW, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR, Mault J, Cruz A, Crowley JJ, Bunn Jr. P. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. *The Journal of Thoracic and Cardiovascular Surgery* March:429-439, 2000.
207. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *The Lancet* 355(9217):1757-1770, 2000.
208. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. *Control Clin Trials* 21(4):343-359, 2000.
209. Liu PY, Anderson G, Crowley J. Observational studies and randomized trials: Letter to the editor. *N Engl J Med* 343(16):1195, 2000.
210. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi N, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Results of high dose therapy for 1,000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. *Blood* 95:4008-4010, 2000.
211. Rusch VW, Giroux DJ, Kraut MJ, Crowley JJ, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *Journal of Thoracic and Cardiovascular Surgery* 121(3):472-483, 2001.
212. Gooley TA, Leisenring W, Crowley J, Storer BE. Why Kaplan-Meier Fails and Cumulative Incidence Succeeds When Estimating Failure Probabilities in the Presence of Competing Risks. In: Crowley J, ed. *Handbook of Statistics in Clinical Oncology*. Marcel-Dekker, New York. pp. 513-523, 2001.
213. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). *Blood* 98:41-48, 2001.
214. Kelly K, Crowley JJ, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase II trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced Non-Small-Cell lung cancer: A Southwest Oncology Group Trial. *Journal of Clinical Oncology* 19(13):3210-3218, 2001.

215. Thomas CR, Giroux DJ, Janaki LM, Turrisi AT, Crowley JJ, Taylor SA, McCracken JD, Shankir Giri PG, Gordon W, Livingston RB, Gandara DR. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. *Lung Cancer* 33(2-3):213-219, 2001.
216. Crowley J, Jacobson J, Alexanian R. Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience. *Seminars in Hematology* 38(3):203-208, 2001.
217. Hoque A, Albanes D, Lippman SM, Spitz D, Taylor PR, Klein E, Thompson IM, Goodman PJ, Stanford JL, Crowley JJ, Coltman CA, Santella RM. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Cancer Causes and Control* 12:627-633, 2001.
218. Faraggi D, LeBlanc M, Crowley J. Understanding neural networks using regression trees: an application to multiple myeloma survival data. *Stat Med* 20:2965-2976, 2001.
219. Kelly K, Lovato L, Bunn Jr. PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley J, Gandara DR. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. *Clin Cancer Res* 7:2325-2329, 2002.
220. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassass A, Crowley J, Tricot G, Barlogie B and Shaughnessy S. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. *Blood* 99:1745-1757, 2002.
221. Weick JK, Crowley JJ, Hussein MA, Moore DF, Barlogie B. The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group study. *Invest New Drugs* 20:117-121, 2002.
222. Moinpour CM, Lyons B, Grevstad P, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR. Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial. *Quality of Life Research* 11:115-126, 2002.
223. Berenson R, Crowley JJ, Grogan TM, Zangari M, Briggs AD, Mills GM, Barlogie B, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. *Blood* 99(9):3163-3168, 2002.
224. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, and Gandara DR. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. *J Natl Cancer Inst* 94(4):291-297, 2002.
225. Albain K, Crowley JJ, Turrisi III AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB Non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. *Journal of Clinical Oncology* 20(16):3454-3460, 2002.
226. LeBlanc M, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. *Stat Methods Med Res* 11:247-274, 2002.
227. Pauler DK, Gower KB, Goodman PJ, Crowley JJ, Thompson IM. Biomarker-based methods for determining noncompliance in a prevention trial. *Control Clin Trials* 23:675-685, 2002.
228. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group study S9504. *Journal of Clinical Oncology* 21(10):2004-2010, 2003.
229. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 349(3):215-224, 2003.

230. Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley J. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. *British Journal of Haematology* 122:441-450, 2003.
231. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux DJ, Crowley J, Hough A, Sawyer J. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. *British Journal of Haematology* 122:430-440, 2003.
232. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic Factors and Response to Fludarabine Therapy in Waldenstrom's Macroglobulinemia: an update of the US Intergroup trial (SWOG S9003). *Seminars in Oncology* 30(2):220-225, 2003.
233. Unger JM, LeBlanc M, Crowley JJ, Grossman B, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA III, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, and Coltman CA Jr. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: The Karnofsky memorial lecture. *Journal of Clinical Oncology* (21)23:246-252, 2003.
234. Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. *Journal of Clinical Oncology* 22(1): 127- 132, 2004.
235. Tangen C, Goodman P, Crowley J and Thompson I. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. *J Urol* 171:S64-S67, 2004.
236. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ and Coltman Jr. CA. Prevalence of prostate cancer among men with prostate-specific antigen level ≤ 4.0 ng per milliliter. *N Engl J Med* 350(22):2239-2246, 2004.
237. Durie BGM, Jacobson J, Barlogie B and Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group Chemotherapy Trials. *Journal of Clinical Oncology* 22(10):1857-1863, 2004.
238. Hardin J, Waddell M, Page CD, Zhan F, Barlogie B, Shaughnessy J and Crowley J. Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma. *Statistical Applications in Genetics and Molecular Biology* 3(1):1-21, 2004.
239. Gandara D, West H, Chansky K, Davies A, Lau D, Crowley J, Gumerlock P, Hirsch F and Franklin W. Bronchioloalveolar carcinoma: A model for investigating the biology of epidermal growth factor receptor inhibition. *Clin Cancer Res* 10(suppl):4205s-4209s, 2004.
240. IASLC. An open letter to all members of the IASLC. *Lung Cancer* 45:119-120, 2004.
241. Edelman, MJ, Clark JL, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J and Gandara D. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. *Clin Cancer Res* 10:5022-5026, 2004.
242. Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr., Ford LG and Thompson I. Implementation of the Prostate Cancer Prevention Trial (PCPT). *Control Clin Trials* 25:203-222, 2004.
243. Pauler DK, Hardin J, Faulkner JR, LeBlanc M, Crowley JJ. Survival Analysis with Gene Expression Arrays. In: Balakrishnan N; Rao CR, editors. *Handbook of Statistics*. Volume 23. Amsterdam: Elsevier; 2004. p. 675-688.
244. Le Q.-T., McCoy J, Williamson S, Le Q-T, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, and Gandara DR. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. *Clin Cancer Res* 10:5418-5424, 2004.

245. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, Barlogie B. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. *Blood* 104(12):3520-3526, 2004.
246. Lippman S, Goodman P, Klein E, Parnes H, Thompson IM Jr., Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas S, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Leiber MM, Walther PH, Khuri FR, Karp DD, Schwartz GG, Ford LG and Coltman CA Jr. Designing the Selenium and Vitamin E cancer prevention trial (SELECT). *J Natl Cancer Inst* 97(2):94-102, 2005.
247. Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA, Jr. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. *Cancer* 103(7):1375-1380, 2005.
248. Crowley J. Clinical Trials Design. In: Shields TW; Locicero III, J; Ponn RB; Rusch VW, editors. *General Thoracic Surgery*, v I. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1414-1421.
249. Brown G and Crowley J. Is there any hope for Vitamin E? *JAMA* 293(11):1387-1390, 2005. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB and Gandara DR. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: A retrospective review by the Southwest Oncology Group. *Journal of Clinical Oncology* 23(13):2955-2961, 2005.
250. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Harousseau JL, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International Staging System for Multiple Myeloma. *Journal of Clinical Oncology* 23(15):1-9, 2005.
251. Jagannath, S., Durie BGM, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. *British Journal of Hematology* 129:776-783, 2005.
252. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn Jr PA, Franklin WA, Crowley JJ and Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. *Journal of Clinical Oncology* 23(36): 2005.
253. LeBlanc M, J Moon and J Crowley. Adaptive risk group refinement. *Biometrics* 61:370-378, 2005.
254. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL and Coltman CA Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. *JAMA* 294(1), 2005.
255. Williamson S, Crowley JJ, Lara Jr. PN, McCoy J, Lau DHM, Tucker RW, Mills GM and Gandara DR. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. *Journal of Clinical Oncology* 23(36):9097-9104, 2005.
256. Turrisi A, Crowley J, Albain K, Gaspar L and Gandara D. Southwest Oncology Group: two decades of experience in non-small cell lung cancer. *Seminars in Oncology* 32(supp 3):119-121, 2005.
257. Unger JM, Coltman CA Jr, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. *J Clin Oncol*. 2006 Jan 1;24(1):141-4. Epub 2005 Dec 5. PubMed PMID: 16330670.

258. Barlogie B, Kyle R, Anderson K, Greipp P, Lazarus H, Hurd D, McCoy J, Dakhil S, Lanier K, Chapman C, Cromer J, Salmon S, Durie B and Crowley J. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. *Journal of Clinical Oncology* 24(6):929-935, 2006.
259. Hesketh P, Chansky K, Lau DHM, Doroshow JH, Moinpour C, Chapman RA, Goodwin W, Gross HM, Crowley JJ and Gandara DR. Sequential vinorelbine and docetaxel in advanced Non-small-cell lung cancer patients age 70 and older and/or with a performance status of 2: A phase II trial of the Southwest Oncology Group (s0027). *Journal of Thoracic Oncology* 1(6):537-544, 2006.
260. Hesketh P, McCoy J, Dunphy II FR, Bearden III JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ and Gandara DR. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. *Journal of Thoracic Oncology* 1(9):991-995, 2006.
261. Lara Jr. P, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ and Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group Phase II Trial (S0327). *Journal of Thoracic Oncology* 1(9):996-1001, 2006.
262. Goldstraw P and Crowley J. The International Association for the Study of Lung Cancer international staging project on lung cancer. *Journal of Thoracic Oncology* 1(4):281-286, 2006.
263. Goodman P, Thompson IM, Tangen CM, Crowley J, Ford LG and Coltman Jr. CA. The prostate cancer prevention trial: design, biases and interpretation of study results. *Journal of Urology* 175:2234-2242, 2006.
264. Caban-Holt AM, Schmitt FA, Runyons CR, Kryscio RJ, Medidondo MS, Healey MS, Markesbery WR, Coltman Jr. CA, Crowley JJ, Goodman PJ and Hartline JL. Studying the effects of Vitamin E and Selenium for Alzheimer's disease prevention: the Preadvise model. *Research and Practice in Alzheimer's Disease* 11:124-130, 2006.
265. Hanamura I, Stewart J, Huang Y, Zhan F, Santra M, Sawyer J, Hollmig K, Zangari M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B and Shaughnessy Jr. J. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloms and is related to prognosis and disease progression following tandem stem-cell transplantation. *Blood* 108(5):1724-1732, 2006.
266. Davies AM, Chansky K, Lau DHM, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley J, Gandara DR. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III Non-Small-Cell lung cancer: SWOG S9712. *Journal of Clinical Oncology* 24(33):5242-5246, 2006.
267. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara Jr. PN, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB Non-Small-Cell lung cancer: a phase II Southwest Oncology Group study (S9504). *Clinical Lung Cancer* 8(2):116-121, 2006.
268. Govindan R, Crowley J, Schwartzberg, L, Kennedy P, Williams C, Ekstrand B, Sandler A, Juanakais D, Bolejack V and Ghalie R. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. *Journal of Clinical Oncology* 24(30):4848-4854, 2006.
269. Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J and Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. *Clinical Lymphoma Myeloma* 6(6):469-474, 2006.
270. West HL, Franklin WA, McCoy J, Gumerlock P, Vance R, Lau DHM, Chansky K, Crowley JJ, Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126. *Journal of Clinical Oncology* 24(12):1807-1813, 2006.

271. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med* 354(10):1021-30, 2006. PMID: 16525139.
272. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B and Shaughnessy Jr. JD. The molecular classification of multiple myeloma. *Blood* 108(6):2020-2028, 2006.
273. Tangen CM and Crowley J. Phase II Trails and Time-to-Event Endpoints. In Crowley J and Ankerst DP Eds. *Handbook of Statistics in Clinical Oncology, 2nd Edition*. Chapman & Hall/CRC New York. pp 143-155, 2006.
274. LeBlanc M, Rasmussen E and Crowley J. Constructing Prognostic Groups by Tree-Based Partitioning and Peeling Methods. In Crowley J and Ankerst DP Eds. *Handbook of Statistics in Clinical Oncology, 2nd Edition*. Chapman & Hall/CRC New York. pp 365-382, 2006.
275. Gooley TA, Leisenring W, Crowley J and Storer BE. Estimation of Cumulative Incidence in the Presence of Competing Risks. In Crowley J and Ankerst DP Eds. *Handbook of Statistics in Clinical Oncology, 2nd Edition*. Chapman & Hall/CRC New York. pp 557-566, 2006.
276. Sequential Randomization. Pater J and Crowley J. In Crowley J and Ankerst DP Eds. *Handbook of Statistics in Clinical Oncology, 2nd Edition*. Chapman & Hall/CRC New York. pp 589-596, 2006.
277. Hoering A, Crowley J. Clinical Trial Designs for Multiple Myeloma. *Clinical Advances in Hematology & Oncology* 5(4):309-318, 2007.
278. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr. JD, Epstein J, van Hemert R, Erden E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J and Angtuaco EJ. Magnetic resonance in multiple myeloma: diagnostic and clinical implications. *Journal of Clinical Oncology* 25(9):1121-1128, 2007.
279. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB and Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of southwest oncology group trial 9416 (intergroup trial 0160). *Journal of Clinical Oncology* 25(3):313-318, 2007.
280. Redman M and Crowley J. Small randomized trials. *Journal of Thoracic Oncology* 2(1):1-2, 2007.
281. Hesketh PJ, Lilenbaum RC, Chansky KC, Dowlatti A, Graham P, Chapman RA, Crowley J and Gandara D. Chemotherapy in patients > 80 with advanced non-small-cell lung cancer: combined results from SWOG 0027 and LUN 6. *Journal of Thoracic Oncology* 2(6): 494-498, 2007.
282. Akerley W, McCoy J, Hesketh PJ, Goodwin W, Bearden JD, Atkins JN, Chansky K, Crowley J and Gandara D. Gemcitabine and Irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. *Journal of Thoracic Oncology* 2(6): 526-530, 2007.
283. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood* 109(6):2276-84, 2007. PMID: 17105813.
284. Hesketh P, Chansky K, Isreal V, Grapski R, Mekhail T, Spriidonidis C, Mills G, Kelly K, Crowley J and Gandara D. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group study 9718. *Journal of Thoracic Oncology* 2(5):440-444, 2007.

285. Rami-Porta R, Ball D, Crowley J, Grioux D, Jett J, Travis W, Tsuboi M, Vallieres E and Goldstraw P. The IASLC Lung Cancer staging project: proposals for the revision of the T descriptors in the forthcoming (Seventh) edition of the TNM Classification for lung cancer. *Journal of Thoracic Oncology* 2(7):593-602, 2007.
286. Rusch V, Crowley J, Giroux D, Goldstraw P, Im J, Tsuboi M, Tshuchiya R and Vansteenkiste J. The IASLC Lung Cancer staging project: proposals for the revision of the N descriptors in the forthcoming (seventh) edition of the TNM Classification for lung cancer. *Journal of Thoracic Oncology* 2(7):603-612, 2007.
287. Sheperd F, Crowley J, Van Houtte P, Postmus P, Carney D, Chansky K, Shaikh Z and Goldstraw P. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *Journal of Thoracic Oncology* 2(12):1067-1077, 2007.
288. Haessler J, Shaughnessy JJ, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G and Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. *Clinical Cancer Research* 12(23):7073-7079, 2007. haughnessy JD Jr., Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Graziutti M, Epstein J, Crowley J and Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. *British Journal of Haematology* 127(6):530-536, 2007.
289. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J and Shaughnessy JD Jr. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. *British Journal of Haematology* 138(2):176-185, 2007.
290. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J and Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. *Blood* 111(1):94-100, 2008.
291. Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J and Barlogie B. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. *British Journal of Haematology* 141(4):433-444, 2008.
292. Lara Jr. P, Redman M, Kelly K, Edelman J, Williamson S, Crowley J and Gandara D. Disease control rate at 8 weeks predicts clinical benefit in advanced Non-Small-cell lung cancer: results from Southwest Oncology Group Randomized Trials. *Journal of Clinical Oncology* 26(3):463-467, 2008.
293. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy JJ, Epstein J and Crowley J. The Arkansas approach to therapy of patients with multiple myeloma. *Best Practice & Research Clinical Haematology* 20(4):761-781, 2008.
294. Blanke C, Rankin C, Demetri G, Ryan C, von Mehren M, Benjamin R, Raymond A, Branwell V, Baker L, Maki R, Tanaka M, Hecht J, Heinrich M, Fletcher C, Crowley J and Borden E. Phase III Randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *Journal of Clinical Oncology* 26:626-632, 2008.
295. Barlogie B, van Rhee F, Shaughnessy JD Jr., Anaissie E and Crowley J. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. *Leukemia* 22(8):1633-1636, 2008.

296. Pineda-Roman M, Zangari M, Anaissie E, Tricot G, Van Rhee F, Crowley J, Shaughnessy JD Jr. and Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. *British Journal of Haematology* 140:625-634, 2008.
297. Goldman B, LeBlanc M and Crowley J. Interim futility analysis with intermediate endpoints. *Clinical Trials* 5:14-22, 2008.
298. Mok T and Crowley J. Big question, small answer. *Journal of Thoracic Oncology* 3(2):105-106, 2008.
299. Travis WD, Brambilla E, Rami-Porta R, Vallieres E, Tsuboi M, Rusch V, Goldstraw P, International Staging Committee. Visceral plueral invasion: pathologic criteria and use of elastic stains. Proposal of the 7th edition of the TNM classification for Lung Cancer. *Thoracic Oncology* 3(12):1384-1390, 2008.
300. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy JD Jr., Epstein J and Barlogie B. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. *Leukemia* 24:1-9, 2008.
301. van Rhee F, Shaughnessy JD Jr., Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S and Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade later. *Blood* 112(4):1035-1038, 2008.
302. Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K, Alsayed Y, Epstein J and Shaughnessy JD Jr. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. *Cancer*: 2008.
303. Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B and Crowley J. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. *Cancer* 112(12):2720-2725, 2008.
304. Kelly K, Chansky K, Gaspar L, Albain KS, Jett J, Ung YC, Lau DHM, Crowley JJ and Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiationtherapy and docetaxel consolidation in inoperable stage III Non-Small-Cell lung cancer: SWOG s0023. *Journal of Clinical Oncology* 26(15):2450-2456, 2008.
305. Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr., Anaissie E, Crowley J, Barlogie B. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. *Leukemia* 22(4):850-855, 2008.
306. Ludwig H, Durie BGM, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P and Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. *Blood* 111(8):4039-4047, 2008.
307. Hoering A, LeBlanc M and Crowley J. Randomized phase III clinical trial designs for targeted agents. *Clinical Cancer Research* 14(14):4358-4367, 2008.
308. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn Jr. PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in Non-Small-Cell lung cancer patients treated with cetuximab and chemotherapy. *Journal of Clinical Oncology* 26(20):3351-3367, 2008.
309. Barlogie B, van Rhee F, Shaughnessy JD Jr., Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. *Blood* 112(8):3122-3125, 2008.

310. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr., Franklin WA, Le QT, Crowley JJ and Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced Non-Small-Cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. *Journal of Clinical Oncology* 26(29):4771-4776, 2008.
311. van Ness B, Ramos C, Haznadar M, Hoering A, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D and Morgan G. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression free survival. *BMC Med* 8(6):26, 2008.
312. Hesketh PJ, Chansky K, Wozinak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Southwest Oncology Group phase II trial (s0341) of erlotinib (OSI-774) in patients with advanced Non-Small-Cell lung cancer and a performance status of 2. *Journal of Thoracic Oncology* 3(9):1026-1031, 2008.
313. Burington B, Barlogie B, Zhan F, Crowley J and Shaughnessy JD Jr. Tumor cell expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. *Clinical Cancer Research* 14(15):4821-4829, 2008.
314. Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, van Ness B, Morgan GJ. Genetic associations with thalidomide venous thrombotic events in myeloma identified using targeted genotyping. *Blood* 112(13):4924-4934, 2008.
315. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW and P G. The IASLC Lung Cancer Staging Project. Proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology* 3(11):1213-1223, 2008.
316. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollming K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr., Tricot G, Zangari M, Zeldis J, Crowley J. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. *Blood* 112(8):3115-3121, 2008.
317. Borden EC, Klugger H and Crowley J. Apoptosis: a clinical perspective. *Nature Reviews* 7:959, 2008.
318. Nair B, Waheed S, Szymonifka J, Shaughnessy JD Jr., Crowley J and Barlogie B. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. *British Journal of Haematology* 145(1):131-146, 2008.
319. Rubenstein L, Crowley J, Ivy P, LeBlanc M and Sargent DJ. Randomized Phase II Designs. *Clinical Cancer Research* 15(6):1883-1890, 2009.
320. Rami-Porta R, Crowley J and Goldstraw P. The revised TNM staging system for Lung Cancer. *Annals of Thoracic and Cardiovascular Surgery* 15(1):3-9, 2009.
321. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline J, parsons JK, Bearden III JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Leiber WM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Porbstfield JL, Jagpal TJ, Crowley JJ, Meyskens Jr FL, Baker LH and Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. *JAMA* 301(1):39-51, 2009.
322. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P and IASLC staging committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology* 4(5):568-577, 2009.
323. Giroux DJ, Rami-Porta R, Chansky K, Crowley J, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P and IASLC staging committee. The IASLC lung cancer staging project: data elements for the prospective project. *Journal of Thoracic Oncology* 4(6):679-688, 2009.

324. Hoering A, Crowley J, Shaughnessy JD Jr., Hollmig K, Alsayed Y, Szymomifka J, Waheed S, Nair B, van Rhee F, Anaissie E and Barlogie B. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. *Blood* 114(7):1299-1305, 2009.
325. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. *J Clin Oncol*. 2009 May 20; 27(15):2530-5. Epub 2009 Apr 6. PMID: 19349543; PMCID: PMC2684855
326. Chansky K, Sculier JP, Crowley J, Giroux DJ, Van Meerbeeck J and Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: Prognostic factors and pathologic TNM stage in surgically managed Non-small cell lung cancer. *Journal of Thoracic Oncology* 4(7):792-801, 2009.
327. Le QT, Moon J, Redman MW, Williamson SK, Lara Jr. PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore Jr. DF and Gandara D. Phase II study of tirapazamine, cisplatin and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. *Journal of Clinical Oncology* 27(18):3014-3019, 2009.
328. LeBlanc M, Rankin C and Crowley J. Multiple histology phase II trials. *Statistics in Clinical Cancer Research* 15(13):4256-4262, 2009.
329. Albain KS, Unger JM, Crowley J, Coltman CA Jr and Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. *Journal of National Cancer Institute* 101(14):984-992, 2009.
330. Hussein MA, Bolejack V, Zonder JA, Durie BGM, Jakubowiak J, Crowley JJ and Barlogie B. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: A Southwest Oncology Group Trial (S0204). *Journal of Clinical Oncology* 27(21):3510-3517, 2009.
331. Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. *British Journal of Haematology* 145(5):637-41, 2009.
332. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood* 114(10):2068-2076, 2009.
333. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara Jr. PN, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M and Mack PC. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced Non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. *Journal of Clinical Oncology* 27(21):3540-3546, 2009.
334. Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P. IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (Seventh) edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology* 4(9):1049-1059, 2009.
335. Davies AM, Chansky K, Lara Jr. PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ and Gandara DR. Bortezomib plus gemcitabine/carbopatin as first-line treatment of advanced Non-small Cell lung cancer: A phase II Southwest Oncology Group study (S0339). *Journal of Thoracic Oncology* 4(1):87-92, 2009.
336. Crowley J. Message from John Crowley. In: Taraguchi, Yoko; editor. Dr. Masanori Fukushima's Memoirs. Kyoto: Nakanishi Publishing Company; 2009. p. 24-31.

337. Dhodapkar MV, Hoering A, Gertz MA, Rivkin SE, Szymonifka J, Crowley J and Barlogie B. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003. *Blood* 113(4):793-796, 2009.
338. Durie BG, Van Ness B, Ramos C, Stephens O, Haznadar M, Hoering A, Haessler J, Katz MS, Mundy GR, Kyle RA, Morgan GJ, Crowley J, Barlogie B, Shaughnessy J Jr.(2009). Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. *Leukemia* 23(10):1913-1919, 2009.
339. Shaughnessy JD Jr., Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alasayed Y, Epstein J, Crowley J, Barlogie B. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. *British Journal of Haematology* 147:347-351, 2009.
340. Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. *British Journal of Haematology* 148(4):562-568, 2010.
341. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myeloma, southwest oncology group, and university of Arkansas for medical sciences. *Journal of Clinical Oncology* 28(7):1209-1214, 2010.
342. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westing J, Sonneveld P, Cavo M, Boccadoro M, Paumbo A, Tosi P, Harousseau JL, Barlogie B, Stewart AK, Durie B. Survival and years of life lost in different age cohorts of patients with multiple myeloma. *Journal of Clinical Oncology* 28(9):1599-1605, 2010.
343. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. *Clinical Cancer Research* 16(6):1764-1769, 2010.
344. Rusch VW, Rice TW, Crowley J, Blackstone EH, Rami-Porta R, Goldstraw P. The seventh edition of the American joint committee on cancer/international union against cancer staging manuals: the new era of the data-driven revisions. *J Thoracic Cardiovasc Surg* 139(4):819-821, 2010.
345. Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD Jr., Szymonifka J, Hoering A, Petty N, Crowley J. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. *Journal of Clinical Oncology* 28(18):3023-3027, 2010.
346. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. *Journal of Clinical Oncology* 28(7):1247-1253, 2010.
347. Pisters KM, Vallieres E, Crowley J, Franklin WA, Bunn Jr. PA, Ginsberg RJ, Putnam Jr JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial s9900, an intergroup, randomized, phase III trial. *Journal of Clinical Oncology* 28(11):1843-1849, 2010.
348. Nair B, van Rhee F, Shaughnessy JD Jr., Anaissie E, Szymonifka J, Hoering A, Alasayed Y, Waheed S, Crowley J, Barlogie B. Superior results of total therapy 3 (2033-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. *Blood* 115(21):4168-4173, 2010.

349. Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajeck R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia* 24(6):1121-1127, 2010.
350. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Barlogie B. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. *Blood*. 2010 Aug 26;116(8):1220-7. Epub 2010 May 25. PMC2938233
351. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Agildgarrd N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. *Leukemia*. 2010 Oct;24(10):1700-12. Epub 2010 Sep 2. PMID: 20811404
352. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. *J Clin Oncol*. 2010 Nov 1;28(31):4747-54. Epub 2010 Oct 4. PMC3020704
353. Boffa DJ, Detterbeck FC, Smith EJ, Rami-Porta R, Crowley J, Zelterman D, Tanoue L, Kim AW, Goldstraw PJ. Should the 7th edition of the lung cancer stage classification system change treatment algorithms in non-small cell lung cancer? *J Thorac Oncol*. 2010 Nov;5(11):1779-83. PMID: 20975377
354. Lara Jr PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. *Cancer*. 2010 Dec 15;116(24):5710-5. Epub 2010 Aug 24. PMC2994945
355. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF Sr., Whittenberger BF, Abidi MH, Durie BGM, Barlogie B. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). *Blood*. 2010 Dec 23;116(26):5838-41. Epub 2010 Sep 27. PMC3031379
356. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Bolejack V, Nassir Y, Hilger JD, Sefardi A, Shamouelian A, Swift RA. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. *Am J Hematol*. 2011 Jan;86(1):25-30. PMID: 21120861
357. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozinak AJ, Crowley J, Gandara D. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. *J Thorac Oncol*. 2011 Jan;6(1):115-20. PMC3075557
358. Usmani S, Sexton R, Crowley J, Barlogie B. Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2011 Feb 1;11(1):139-42. PMID: 21454216
359. Hoering A, LeBlanc M, Crowley J. Seamless phase I/II trial design for assessing toxicity and efficacy for targeted agents. *Clin Cancer Res*. 2011 Feb 15;17(4):640-6. Epub 2010 Dec 6. PMID: 21135145

360. Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. *Cancer*. 2011 Mar 1;117(5):1001-9. Epub 2010 Oct 13. PMC3023833
361. Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. *Ann Hematol*. 2011 Apr;90(4):423-8. Epub 2010 Dec 14. PMC3053415
362. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonesca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2. Consensus recommendations for the risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. *Blood*. 2011 May 5;117(18):4696-700. Epub 2011 Feb 3. PMID: 21292777
363. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orłowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood*. 2011 May 5;117(18):4691-5. Epub 2011 Feb 3. PMID: 21292775
364. Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. *Blood*. 2011 Sep 29;118(13):3512-24. Epub 2011 May 31. PMID: 21628408; PMCID: PMC3186329
365. Barlogie B, Crowley J. Could CR mean cure? *Blood*. 2011 Jul 21;118(3):483. PMID: 21778345
366. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for *Helicobacter pylori* infection in seven Latin American sites: a randomized trial. *Lancet*. 2011 Aug 6;378(9790):507-14. PMID: 21777974; PMCID: PMC3313469.
367. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Georger B, Benjamin RS, Helman LJ, Baker LH. R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research through Collaboration Study. *J Clin Oncol*. 2011 Dec 1;29(34):4541-7. Epub 2011 Oct 24. PMID: 22025149; PMCID: PMC3236654.
368. Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH. How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. *Health Aff (Millwood)*. 2011 Dec;30(12):2259-68. PMID: 22147853
369. Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, Waheed S, Shaughnessy JD Jr, Alsayed Y, Heuck CJ, van Rhee F, Milner T, Hoering A, Szymonifka J, Sexton R, Sawyer J, Singh Z, Crowley J, Barlogie B. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. *Leukemia*. 2012 Nov;26(11):2398-405. doi: 10.1038/leu.2012.107. Epub 2012 Apr 17. PubMed PMID: 22508408; PubMed Central PMCID: PMC3426639.

370. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. *Haematologica*. 2012 Nov;97(11):1761-7. doi: 10.3324/haematol.2012.065698. Epub 2012 Jun 11. PubMed PMID: 22689675; PubMed Central PMCID: PMC3487453.
371. Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. *Blood*. 2012 Aug 23;120(8):1597-600. Epub 2012 Jun 6. PMID: 22674807
372. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, AlSayed Y, Vanrhee F, Barlogie B. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? *Leukemia*. 2013 Jan;27(1):226-32. doi: 10.1038/leu.2012.160. Epub 2012 Jun 18. PubMed PMID: 22705990; PubMed Central PMCID: PMC3744094.
373. Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, Van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. *Haematologica*. 2012 Jun 24. [Epub ahead of print] PMID: 22733020.
374. Caban-Holt A, Abner E, Kryscio RJ, Crowley JJ, Schmitt FA. Age-expanded normative data for the ruff 2&7 selective attention test: evaluating cognition in older males. *Clin Neuropsychol*. 2012 Jul;26(5):751-68. Epub 2012 May 31. PMID: 22651854.
375. Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. *Clin Cancer Res*. 2012 Jul 15;18(14):3731-6. Epub 2012 Jun 6. PMID: 22675175.
376. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. *Clin Cancer Res*. 2012 Aug 1;18(15):4004-12. Epub 2012 May 16. PMID: 22592956; PMCID: PMC3409929
377. Baker LH, Crowley JJ, Maki RG. Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). *Oncologist*. 2012;17(9):1129-32. Epub 2012 Aug 22. PMID: 22915060; PMCID: PMC3448404.
378. Crowley J. Clinical trial designs for early drug development: Implications for design with targeted agents (transcript of talk given at the Progress Conference 2011 of Coordination, Support and Training Program for Translational Research). *Clin Eval* 2012; 40 (Suppl XXXI) 185-190.
379. Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD Jr, Usmani SZ, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley J, Barlogie B. Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. *Clin Cancer Res*. 2012 Oct 1;18(19):5499-506. doi: 10.1158/1078-0432.CCR-12-0019. Epub 2012 Aug 1. PMID: 22855579.
380. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. *Br J Haematol*. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18. PMID: 22804669.
381. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypedX-guided management for women with breast cancer involving lymph nodes. *Contemp Clin Trials*. 2013 Jan;34(1):1-9. doi: 10.1016/j.cct.2012.09.003. Epub 2012 Sep 18. PMID: 23000081; PMCID: PMC3525786.

382. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. *Leukemia*. 2012 Oct 3. doi: 10.1038/leu.2012.282. [Epub ahead of print] PMID: 23032723.
383. Goodman PJ, Hartline JA, Tangen CM, Crowley JJ, Minasian LM, Klein EA, Cook ED, Darke AK, Arnold KB, Anderson K, Yee M, Meyskens FL, Baker LH. Moving a randomized clinical trial into an observational cohort. *Clin Trials*. 2012 Oct 12. [Epub ahead of print] PMID: 23064404.
384. Barlogie B, Crowley J. Prognostic implications of cumulative dosing in total therapy 3. *Blood*. 2012 Oct 18;120(16):3383-5. doi: 10.1182/blood-2012-05-426809. PMID: 23086625.
385. Matsui S, Simon R, Qu P, Shaughnessy JD Jr, Barlogie B, Crowley J. Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. *Clin Cancer Res*. 2012 Nov 1;18(21):6065-73. doi: 10.1158/1078-0432.CCR-12-1206. Epub 2012 Aug 27. PMID: 22927484.
386. Goodman K, Krueger J, Crowley J. The automatic clinical trial: leveraging the electronic medical record in multisite cancer clinical trials. *Curr Oncol Rep*. 2012 Dec;14(6):502-8. doi: 10.1007/s11912-012-0262-8. PMID: 22907283; PMCID: PMC3490046.
387. Abner EL, Dennis BC, Mathews MJ, Mendiondo MS, Caban-Holt A, Kryscio RJ, Schmitt FA; PREADViSE Investigators, Crowley JJ; SELECT Investigators. Practice effects in a longitudinal, multi-center Alzheimer's disease prevention clinical trial. *Trials*. 2012 Nov 20;13:217. doi: 10.1186/1745-6215-13-217. PMID: 23171483; PMCID: PMC3543284.
388. Hoering A, LeBlanc M and Crowley JJ. Seamless Phase I/II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents. In Crowley J and Hoering A Eds, *Handbook of Statistics in Clinical Oncology, 3rd edition*. CRC Press/Chapman and Hall, London. pp 97-108, 2012.
389. Tangen CM and Crowley JJ. Designs Using Time-to-Event Endpoints/Single-Arm versus Randomized Phase II Designs. In Crowley J and Hoering A Eds, *Handbook of Statistics in Clinical Oncology, 3rd edition*. CRC Press/Chapman and Hall, London. pp 139-150, 2012.
390. Anderson GL, LeBlanc M, Liu PY and Crowley J. Use of Covariates in Randomization and Analysis of Clinical Trials. In Crowley J and Hoering A. Eds. *Handbook of Statistics in Clinical Oncology, 3rd Edition*. CRC Press/Chapman and Hall, London. pp 139-150, 2012.
391. Hoering A, LeBlanc M and Crowley JJ. Phase III Trials for Targeted Agents. In Crowley J and Hoering A. Eds. *Handbook of Statistics in Clinical Oncology, 3rd Edition*. CRC Press/Chapman and Hall, London. pp 251-264, 2012.
392. Othus M, Crowley JJ and Barlogie B. Cure-Rate Survival models in Clinical Trials. In Crowley J and Hoering A. Eds. *Handbook of Statistics in Clinical Oncology, 3rd Edition*. CRC Press/Chapman and Hall, London. pp 325-338, 2012.
393. LeBlanc M and Crowley J. Prognostic Groups by Tree-based Partitioning and Data Refinement Methods. In Crowley J and Hoering A. Eds. *Handbook of Statistics in Clinical Oncology, 3rd Edition*. CRC Press/Chapman and Hall, London. pp 505-528, 2012.
394. Qu P, Shaughnessy J Jr., Barlogie B and Crowley JJ. Developing a Score Based upon Gene Expression Profiling and Validation. In Crowley J and Hoering A. Eds. *Handbook of Statistics in Clinical Oncology, 3rd Edition*. CRC Press/Chapman and Hall, London. pp 555-568, 2012.
395. Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ. Patient income level and cancer clinical trial participation. *J Clin Oncol*. 2013 Feb 10;31(5):536-42. doi: 10.1200/JCO.2012.45.4553. PMID: 23295802; PMCID: PMC3565180.
396. Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, Dennis BC, Mathews M, Klein EA, Crowley JJ. A Randomized Controlled Alzheimer's Disease Prevention Trial's Evolution into an Exposure Trial: The PREADViSE Trial. *J Nutr Health Aging*. 2013;17(1):72-5. doi: 10.1007/s12603-012-0083-3. PMID: 23299383.

397. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. *Blood*. 2013 Mar 7;121(10):1819-23. doi: 10.1182/blood-2012-08-451690. PMID: 23305732; PMCID: PMC3591801.
398. Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent *Helicobacter pylori* infection 1 year after initial eradication therapy in 7 Latin American communities. *JAMA*. 2013 Feb 13;309(6):578-86. doi: 10.1001/jama.2013.311. PMID: 23403682; PMCID: PMC3697935.
399. Hoering A, Mitchell A, LeBlanc M, Crowley J. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents. *Clin Trials*. 2013;10(3):422-9. doi: 10.1177/1740774513480961. PMID: 23529697; PMCID: PMC3744092.
400. Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk Factors for MDS and Acute Leukemia Following Total Therapy 2 and 3 for Multiple Myeloma. *Blood*. 2013 Apr 19. [Epub ahead of print] PMID: 23603914.
401. Korn RL, Crowley JJ. Overview: progression-free survival as an endpoint in clinical trials with solid tumors. *Clin Cancer Res*. 2013 May 15;19(10):2607-12. doi: 10.1158/1078-0432.CCR-12-2934. Review. PMID: 23669420; PMCID: PMC3654394.
402. Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D Jr, Keller J, Waheed S, Usmani SZ, Van Rhee F, Bailey C, Petty N, Hoering A, Crowley J, Barlogie B. Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. *Haematologica*. 2013 Jul;98(7):1147-53. doi: 10.3324/haematol.2013.085183. PMID: 23716540; PMCID: PMC3696620.
403. Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). *Blood*. 2014 Jan 2;123(1):78-85. doi: 10.1182/blood-2013-07-515239. PMID: 24144643; PMCID: PMC3879908.
404. Dettner FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. *J Thorac Oncol*. 2013 Dec;8(12):1467-73. doi: 10.1097/JTO.000000000000017. PMID: 24389429.
405. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetz SM, Chow WA, Helman LJ. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. *Cancer*. 2014 May 2. doi: 10.1002/cncr.28728. [Epub ahead of print] PMID: 24797726.
406. Philip PA, Chansky K, Rubinstein L, LeBlanc M, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single Arm Phase II Trials. *Clin Cancer Res*. 2014 Jun 9. pii: clincanres.2024.2013. [Epub ahead of print] PMID: 24914040.

407. Christen WG, Glynn RJ, Gaziano JM, Darke AK, Crowley JJ, Goodman PJ, Lippman SM, Lad TE, Bearden JD, Goodman GE, Minasian LM, Thompson IM Jr, Blanke CD, Klein EA. Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study: A Randomized Clinical Trial. *JAMA Ophthalmol.* 2014 Sep 18. doi: 10.1001/jamaophthalmol.2014.3478. [Epub ahead of print] PubMed PMID: 25232809.
408. Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Lucchi M, Marino M, Marom EM, Nicholson AG, Ruffini E; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. *J Thorac Oncol.* 2014 Sep;9(9 Suppl 2):S81-7. doi: 10.1097/JTO.0000000000000291. PMID: 25396316.
409. Nicholson AG, Detterbeck FC, Marino M, Kim J, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Giaccone G, Huang J, Kondo K, Lucchi M, Marom EM, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. *J Thorac Oncol.* 2014 Sep;9(9 Suppl 2):S73-80. doi: 10.1097/JTO.0000000000000303. PMID: 25396315.
410. Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. *J Thorac Oncol.* 2014 Sep;9(9 Suppl 2):S65-72. doi: 10.1097/JTO.0000000000000290. PMID: 25396314
411. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. *Blood.* 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7. PMID: 25293776.
412. Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions. The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol.* 2014 Nov;9(11):1618-24. doi: 10.1097/JTO.0000000000000334. PMID: 25436796.
413. Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A, Crowley J, Barlogie B. Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. *Leukemia.* 2014 Dec;28(12):2410-3. PMID: 25079174; PMCID: PMC4274609.
414. Crowley J., Qu P. and Barlogie B. 2014. Ethical issues in getting it right: Using Big Data to determine medical treatment. In *JSM Proceedings*, Committee on professional Ethics. Alexandria, VA: American Statistical Association. 56-67.
415. Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B. Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. *BMC Bioinformatics.* 2015 Feb 25;16(1):63. doi: 10.1186/s12859-015-0478-3. PMID: 25887219; PMCID: PMC4355992.
416. Cassano PA, Guertin KA, Kristal AR, Ritchie KA, Bertoia ML, Arnold KB, Crowley JJ, Hartline J, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Klein E. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. *Respir Res.* 2015 Mar 11;16(1):35. [Epub ahead of print] PMID: 25889509; PMCID: PMC4404242.

417. Khan R, Apewokin S, Graziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. *Leukemia*. 2015 May;29(5):1195-201. doi: 10.1038/leu.2015.15. Epub 2012 Feb 2. PMID: 25640885; PMCID: PMC4430702.
418. Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). *Haematologica*. 2015 May 28. pii: haematol.2015.124651. [Epub ahead of print] PMID: 26022710.
419. Qu P, Barlogie B, Crowley J. Using a latent class model to refine risk stratification in multiple myeloma. *Stat Med*. 2015 Sep 20;34(21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17. PubMed PMID: 26084662.
420. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol*. 2015 Jul;10(7):990-1003. doi: 10.1097/JTO.0000000000000559. PubMed PMID: 26134221.
421. Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B. Risk of multiple myeloma in a case-spouse study. *Leuk Lymphoma*. 2015 Sep 30:1-27. [Epub ahead of print] PMID: 26422532.
422. Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B. Prospective analysis of antigen-specific immunity, stem cell antigens and immune checkpoints in monoclonal gammopathy. *Blood*. 2015 Oct 14. pii: blood-2015-03-632919. [Epub ahead of print] PMID: 26468228.
423. Eberhardt W, Mitchell A, Crowley JJ, Kondo H, Kim Y, Turrisi A, Goldstraw P, Rami-Porta R; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol*. 2015 Nov;10(11):1515-1522. PMID: 26536193
424. Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol*. 2015 Dec;10(12):1675-84. doi: 10.1097/JTO.0000000000000678. PubMed PMID: 26709477.
425. Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J, Rami-Porta R; Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol*. 2016 Mar;11(3):300-11. doi: 10.1016/j.jtho.2015.10.008. Epub 2015 Dec 24. PMID: 26723244.

426. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol*. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009. PMID: 26762738.
427. Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, Rami-Porta R; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol*. 2016 May;11(5):681-92. doi: 10.1016/j.jtho.2015.12.114. PMID: 26940530.
428. Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *J Thorac Oncol*. 2016 May;11(5):639-50. doi: 10.1016/j.jtho.2016.01.024. PMID: 26940528.
429. Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR. Risk of Skin Cancer in Multiple Myeloma Patients: A Retrospective Cohort study. *Eur J Haematol*. 2016 Feb 13. doi: 10.1111/ejh.12748. [Epub ahead of print] PMID: 26872804
430. Papanikolaou X, Rosenthal A, Dhodapkar M, Epstein J, Khan R, van Rhee F, Jethava Y, Waheed S, Zangari M, Hoering A, Crowley J, Alapat D, Davies F, Morgan G, Barlogie B. Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). *Blood Cancer J*. 2016 Mar 25;6:e410. doi: 10.1038/bcj.2016.19. PMID: 27015287.
431. Crowley JJ. IBS Past Presidents: Norman Breslow. *Biometric Bulletin*. 2016 Jan-Mar;33(1).
432. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuitatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. *Cancer Cell*. 2016 May 9;29(5):639-52. PMID: 27132469.
433. Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. *Blood Cancer J*. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64. PMID: 27471869.
434. Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. *Trials*. 2016 Aug 12;17:400. doi: 10.1186/s13063-016-1524-9. PMID: 27519183; PMCID: PMC4983010.

435. Detterbeck FC, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L, Kennedy C, Krasnik M, Peake M, Rami-Porta R; IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol*. 2016 Sep;11(9):1433-46. doi: 10.1016/j.jtho.2016.06.028. Epub 2016 Jul 21. PMID: 27448762.
436. Valdivieso M, Bussalleu A, Sexton R, Boehnke K, Osorio S, Novoa Reyes I, Crowley JJ, Goodman GE, Baker LH, Xi C. Clinical, Epidemiologic, and Genomic Studies (SWOG S1119) of Helicobacter Pylori in Lima, Peru: Role of Contaminated Water. *J Cancerol*. 2016;2:52-63.
437. Heinrich M, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebe DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. *JAMA Oncol*. 2017 Feb 9. doi: 10.1001/jamaoncol.2016.6728. PMID: 28196207.
438. Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. *Infect Drug Resist*. 2017 Mar 10;10:85-90. doi: 10.2147/IDR.S123798. eCollection 2017. PMID: 28331349; PMCID: PMC5354526.
439. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, Yee M, Crowley J, Schmitt FA. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). *JAMA Neurol*. 2017 Mar 20. doi: 10.1001/jamaneurol.2016.5778. [Epub ahead of print] PMID: 28319243.
440. Hoering A, Durie B, Wang H, Crowley J. End points and statistical considerations in immunology trials: impact on multiple myeloma. *Future Oncol*. 2017 Apr 11. doi: 10.2217/fon-2016-0504. PMID: 28395525.
441. Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, Kennedy C, Krasnik M, Peak M, Shemanski L, Bolejack V, Crowley JJ, Asamura H, Rami-Porta R; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol*. 2017 Apr 28. pii: S1556-0864(17)30340-4. doi: 10.1016/j.jtho.2017.04.011. [Epub ahead of print] PMID: 28461257.
442. Matsui S, Noma H, Qu P, Sakai Y, Matsui K, Heuck C, Crowley J. Multi-subgroup gene screening using semi-parametric hierarchical mixture models and the optimal discovery procedure: Application to a randomized clinical trial in multiple myeloma. *Biometrics*. 2018 Mar;74(1):313-320. doi: 10.1111/biom.12716. Epub 2017 May 12. PMID: 28498490.
443. Matsui S, Crowley J. Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design. *Clin Cancer Res*. 2018 Mar 1;24(5):994-1001. doi: 10.1158/1078-0432.CCR-17-1552. Epub 2017 Sep 8. PMID: 28887317.
444. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebe DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol*. 2017 Oct 4. pii: S1470-2045(17)30624-1. doi: 10.1016/S1470-2045(17)30624-1. [Epub ahead of print] PMID: 28988646.
445. Othus M, Mitchell A, Barlogie B, Morgan G, Crowley J. Cure- Rate Survival Models and Their Application to Cancer Clinical Trials. *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*. 2017; 168-178.

446. Crowley J, Mitchell A, Qu P, Morgan G, Barlogie B. Optimal Three-Group Splits Based on a Survival Outcome. *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*. 2017; 231-242.
447. Qu P, Tian E, Barlogie B, Morgan G, Crowley J. An Evaluation of Gene Set Analysis for Biomarker Discovery with Applications to Myeloma Research. *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*. 2017; 413-434.
448. Giroux DJ, Van Schil P, Asamura H, Rami-Porta R, Chansky K, Crowley JJ, Rusch VW, Kernstine K; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. *J Thorac Oncol*. 2018 Feb 22. pii: S1556-0864(18)30131-X. doi: 10.1016/j.jtho.2018.02.012. [Epub ahead of print] PMID: 29476906.
449. Hoering A, Crowley J. Phase III Oncology Clinical Trials. Chapter in *Oncology Clinical Trials, Second Edition: Successful Design, Conduct, and Analysis*; Kevin W, Halabi S, eds. New York. Springer; 2018.
450. Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and Outcome Disparities in Multiple Myeloma: Exploring the Role of Race/Ethnicity in the Cooperative Group Clinical Trials. *Blood Cancer J*. 2018 Jul 6;8(7): 67. Doi: 10.1038/s41408-018-0102-7. PMID: 29476906.
451. Blanke CD, Crowley J, Baker LH, Fisher RI. In Memoriam: Charles A. Coltman, 1930-2018. *Journal of Clinical Oncology*. 2018 37:13, 1037-1040.
452. Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Amon Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. *JAMA Oncol*. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3394. [Epub ahead of print] PMID: 31580386.
453. Edwards JG, Chansky K, Van Schil P, Nicholson AG, Boubia S, Brambilla E, Donington J, Galateau-Salle F, Hoffman H, Infante M, Marino M, Marom EM, Nakajima J, Ostrowski M, Travis WD, Tsao MS, Yatabe Y, Giroux DJ, Shemanski L, Crowley J, Krasnik M, Asamura H, Rami-Porta R, IASLC Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2020 Mar;15(3):344-359. DOI: 10.1016/j.jtho.2019.10.019. PMID: 31731014.
454. von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Jornick JL, Flieder DB, Chugh, Rink L, Van den Abbeele AD. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. *Clin Cancer Res*. 2020 Apr 15;26(8):1837-1845. doi:10.1158/1078-0432.CCR-19-1069. PMID: 31792037.
455. Arnold SM, Chansky K, Baggstrom MQ, Thompson MA, Sanborn RE, Villano JL, Waqar SN, Hamm J, Leggas M, Willis M, Rosales J, Crowley J. Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy. *Clin Lung Cancer*. 2020 Jul;21(4):357-364.e7. doi: 10.1016/j.clcc.2020.01.006. Epub 2020 Jan 27. PMID: 32173247.
456. Ding X, Abner EL, Schmitt FA, Crowley J, Goodman P, Kryscio RJ. Mental Component Score (MCS) from Health-Related Quality of Life Predicts Incidence of Dementia in U.S. Males. *J Prev Alzheimers Dis*. 2020 Sep. <https://doi.org/10.14283/jpad.2020.50>

BOOKS AND EDITED VOLUMES

1. Crowley J, Johnson RA, eds. *Survival Analysis: IMS Lecture Notes, Monograph Series Vol 2*, Hayward, CA: The Institute of Mathematical Statistics, 1982.
2. Green S; Benedetti J; Crowley J. *Clinical Trials in Oncology*. London. Chapman Hall; 1997.
3. Crowley J, ed. *Handbook of Statistics in Clinical Oncology*. New York. Marcel-Dekker. 2001.
4. Green S; Benedetti J; Crowley J. *Clinical Trials in Oncology. Second Edition*. London. CRC Press/Chapman and Hall; 2003. Translated into Japanese by JCOG, Igaku-Shoin Ltd, Japan, 2004.
5. Crowley J; Ankerst D, eds. *Handbook of Statistics in Clinical Oncology. Second Edition*. London. CRC Press/Chapman and Hall; 2006.
6. Crowley J; Hoering A, eds. *Handbook of Statistics in Clinical Oncology. Third Edition*. London. CRC Press/Chapman and Hall; 2012.
7. Green S; Benedetti J; Smith A; Crowley J. *Clinical Trials in Oncology. Third Edition*. London. CRC Press/Chapman and Hall; 2012. Translated into Japanese by JCOG, Igaku-Shoin Ltd, Japan, 2013.
8. Crowley J, ed. PFS: The Endpoint We Love and Love to Hate. *Clin Cancer Res Focus Issue*, Guest Editor. (Susan Bates, Focus Editor); 2013 May 15.
9. Matsui S, Crowley J. *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*. Singapore. Springer; 2017.